Compare
Gilead Sciences vs Incyte (GILD vs INCY)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Gilead Sciences (GILD) returned +36.1% and Incyte (INCY) +13.2%; so far this year the figures are +36.0% and +21.1%.
Gilead Sciences is the larger company by market value, about 8.5 times the size of Incyte.
Revenue grew +6.5% at GILD and +24.9% at INCY over the last year.
GILD yields 1.95%. INCY pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| GILD | INCY | |
|---|---|---|
| Price | $166.89 | $119.65 |
| 1-day | -0.41% | +1.39% |
| YTD | +35.97% | +21.14% |
| 1 year | +36.15% | +13.20% |
| 3 years | +108.12% | +120.07% |
| Market cap | $207.0B | $24.4B |
| P/E | — | 63.6 |
| P/S | 6.68 | 4.06 |
| P/B | 15.87 | 4.32 |
| Revenue growth | +6.50% | +24.90% |
| EPS growth | -149.00% | -68.10% |
| Gross margin % | 79.9 | 92.7 |
| Net margin % | -12.5 | 6.7 |
| ROE % | -29.6 | 7.1 |
| Debt / equity | 2.01 | 3.37 |
| FCF yield % | 6.7 | 3.1 |
| Dividend yield % | 1.95 | — |
| Beta | 0.37 | 0.44 |
| RSI (14) | 60.2 | 53.5 |
| Technical rating |